Novo Nordisk Cuts 2025 Outlook Amid Slowing US Prescription Growth for Wegovy

Novo Nordisk Revises 2025 Forecast

• 📉 Novo Nordisk has lowered its full-year sales forecast for 2025, marking an end to a four-year period of consistent guidance increases.
• ⚠️ This revision follows a lackluster performance in US prescription data for its key obesity drug.

Wegovy Sales Performance

• 📊 First-quarter sales for Wegovy reached $2.64 billion, representing a 13% decrease from the previous quarter.
• 🎯 This sales figure fell short of analyst expectations, contributing to investor concerns.

Market Competition and Valuation

• ⚔️ The slowdown in Wegovy sales may intensify worries about Novo Nordisk's leading position in the competitive obesity drug market, particularly against rival Eli Lilly.
• 💰 Previously Europe's most valuable listed company at $615 billion, Novo Nordisk's market value has since halved to approximately $310 billion.

Prescription Trends and Supply

• 📈 Despite efforts to increase supply to meet demand, US prescriptions for Wegovy have stagnated since February.
• 🌐 The company now anticipates 2025 sales growth in local currencies to be between 13% and 21%, a reduction from the previously projected 16% to 24% range.